|
| Perspective From Industry Leaders |
|
|
| ‘Quiet Giant’ Biocon Sets Out Vision For Biosimilars | Sandoz Feels It Has The Ingredients To Make A Splash In ADCs |
|
Biocon Biologics chief commercial officer for advanced markets Matt Erick says the firm is a “quiet giant... |
Sandoz’s Strategic Review 2024 event gave the firm the chance to speak at length about its aspirations... |
| Licensing & Collaboration Agreements |
|
|
| Moderately Optimistic: Rounding Out Deal Making In 2024 | Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan |
|
Dealmaking trends in 2024 point toward a healthier financial ecosystem than in 2023. However, with... |
Plus deals involving Jiangsu Alphamab/CSPC, Zydus/CDRI, Junshi/JSIAMA, Repair/Genevant... |
| Next Gen R&D |
|
|
| BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions | Kiji Takes Flight With Off-The-Shelf Stem Cells |
|
An upfront payment of $110m from BMS has come just in time for Prime Medicine, but its real test will... |
Industry veteran Miguel Forte navigates new kid on the block Kiji Therapeutics into the clinic to... |
| Clinical Trials |
|
|
| Boehringer Gets The First Phase III Hit In IPF For A Decade | New EU HTA Guidance OKs Single-Arm Studies, But More Work Needed On Evidence Gaps |
|
Nerandomilast improved patients’ lung function to a greater degree than placebo, but safety data will be key... |
New guidance from the European Commission on clinical trial validity for forthcoming joint clinical assessments... |
|
|
|
Citeline Contact Poornachandra Tejasvi .K, 
|
IPA Contact Name: Hari Pranav K |